Practitioner versus medication-expert opinion on psychiatric pharmacotherapy of mentally retarded patients with mental disorders

American Journal of Health-System Pharmacy

Volumn 58, Issue 19, 2001, Pages 1824-1829

  Patel, Nick C ^a   Crismon, M Lynn ^a,b,c   Rush, A John ^d   Frances, Allen ^e  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UTA   (United States)

^c Texas Department of Mental Health   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Antimanic agents; Data collection; Lithium; Mental retardation; Mirtazapine; Protocols; Psychotherapeutic agents; Psychotic disorders; Venlafaxine

Indexed keywords

MIRTAZAPINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ARTICLE; CLINICAL PRACTICE; DEPRESSION; HUMAN; MENTAL DEFICIENCY; MENTAL DISEASE; PHARMACIST; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOPHARMACOTHERAPY;

EID: 0035478917     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/58.19.1824     Document Type: Article

References (29)

1. Diagnostic and statistical manual of mental disorders, fourth edition. Washington, DC: American Psychiatric Association; 1994.
2. Sovner R, Hurley AD. Do the mentally retarded suffer from affective illness? Arch Gen Psychiatry. 1993; 40:61-7.
3. Reiss S, Aman MG, eds. Psychotropic medication and developmental disabilities: the international consensus handbook. Columbus, OH: Ohio State University Nisonger Center; 1998.
4. Singh NN, Sood A, Sonenklar N et al. Assessment and diagnosis of mental illness in persons with mental retardation. Behav Modif. 1991; 15:419-41.
5. Stark JA, Menolascino FJ, Albarelli MH et al. Mental retardation and mental health. New York: Springer-Verlag; 1988.
6. Spreat S, Conroy JW, Jones JC. Use of psychotropic medication in Oklahoma: a statewide survey. Am J Ment Retard. 1997; 102:80-5.
7. McEvoy JP, Scheifler PL, Frances A. The Expert Consensus Guideline Series: treatment of schizophrenia 1999. J Clin Psychiatry. 1999; 60(suppl 11):1-80.
8. March JS, Frances A, Carpenter D et al. The Expert Consensus Guideline Series: treatment of obsessive-compulsive disorder. J Clin Psychiatry. 1997; 58(suppl 4):1-72.
9. Sachs GS, Printz DJ, Kahn DA et al. The Expert Consensus Guideline Series: medication treatment of bipolar disorder 2000. Postgrad Med Spec Rep. 2000; Apr:1-104.
10. Foa EB, Davidson JRT, Frances A. The Expert Consensus Guideline Series: treatment of posttraumatic stress disorder. J Clin Psychiatry. 1999; 60(suppl 16):1-76.
11. Alexopoulos GS, Silver JM, Kahn DA et al. The Expert Consensus Guideline Series: treatment of agitation in older persons with dementia. Postgrad Med Spec Rep. 1998; Apr:1-88.
12. Rush AJ, Frances A, eds. Expert Consensus Guideline Series: treatment of psychiatric and behavioral problems in mental retardation. Am J Ment Retard. 2000; 105:159-226.
13. Brook RH, Chassin MR, Fink A et al. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care. 1986; 2:53-63.
14. Kahn DA, Docherty JP, Carpenter D et al. Consensus methods in practice guideline development: a review and description of a new method. Psychopharmacol Bull. 1997; 33(4):631-9.
15. Hinkle DE, Wiersma W, Jurs SG. Applied statistics for the behavioral sciences. 3rd ed. Boston: Houghton Mifflin; 1994.
16. Trivedi MH, Rush AJ, Crismon ML et al. Treatment guidelines and algorithms. In: Dunner DL, Rosenbaum JF, eds. Psychiatric Clinics of North America annual review of drug therapy 2000. Philadelphia: Saunders; 2000:1-22.
17. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000; 283:373-80.
18. Peay MY, Peay ER. The role of commercial sources in the adoption of a new drug. Soc Sci Med. 1988; 26:1183-9.
19. Crismon ML, Trivedi M, Pigott TA et al. The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry. 1999; 60:142-56.
20. Hirschfield RM. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. J Clin Psychiatry. 1999; 60:326-35.
21. Schatzberg AF. Antidepressant effectiveness in severe depression and melancholia. J Clin Psychiatry. 1999; 60(suppl 4): 14-21.
22. Nelson JC. Safety and tolerability of the new antidepressants. J Clin Psychiatry. 1997; 58(suppl 6):26-31.
23. Ereshefsky L, Riesenman C, Lam YW. Antidepressant drug interactions and the cytochrome P450 system: the role of cytochrome P450 2D6. Clin Pharmacokinet. 1995; 29(suppl 1):10-8.
24. Rouillon F, Gorwood P. The use of lithium to augment antidepressant medication. J Clin Psychiatry. 1998; 59(suppl 5): 32-9.
25. Nelson JC. Augmentation strategies in depression 2000. J Clin Psychiatry. 2000; 61(suppl 2):13-9.
26. Hilton NZ, Simmons JL. Adverse effects of poor behavior management of an inpatient's difficult behaviors. Psychiatr Serv. 1999; 50:964-6.
27. Corrigan PW, McCracken SG, Edwards M et al. Staff training to improve implementation and impact of behavioral rehabilitation programs. Psychiatr Serv. 1997; 48:1336-8.
28. Pathman DE, Konrad TR, Freed GL et al. The awareness-to-adherence model of the steps to clinical guideline compliance. The case of pediatric vaccine recommendations. Med Care. 1996; 34:873-89.
29. Christakis DA, Rivara FP. Pediatricians' awareness of and attitudes about four clinical practice guidelines. Pediatrics. 1998; 101:825-30.